Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

OptimizeRx Q3 2026 Results: Net Income $1.2M, Up 53.4% YoY

For the three months ended September 30, 2026, OptimizeRx reported net revenue of $21.6 million and net income of $1.2 million, compared to $26.1 million and $0.8 million in the prior year period. While quarterly profitability improved, the company recorded a slight net loss of $3,000 for the nine-month period as revenues declined from $77.2 million to $62.0 million year-over-year.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue21.626.1
Profit before tax2.61.1
Net income1.20.8
EPS (diluted, $ a share)$0.06$0.04

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Net income, year on year+53.4%
Revenue, year on year-17.1%
Operating margin12.4%
Source

10-Q filed with the SEC, NASDAQ: OPRX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

OptimizeRx Corp: key numbers

Share price
$6.64Close, Nov 16
Market cap
$126M
Shares outstanding
18.91MLatest SEC cover page
Sector
Trade & Services
Industry
Services-Business Services, NECSIC 7389

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from OptimizeRx Corp

All →
4:08 PM ET 8-K
Financial Results

OptimizeRx Financial Results

OptimizeRx reported Q3 2026 revenue of $21.6 million, a 17% year-over-year decrease, while GAAP net income rose to $1.2 million. The company updated its full-year 2026 revenue guidance to $87-$93 million but maintained its adjusted EBITDA outlook. Management highlighted significant margin expansion and a reduction in debt principal to $10.4 million.

Term
Q3 2026

“Third quarter revenue and adjusted EBITDA both exceeded consensus expectations, reflecting continued margin expansion, disciplined execution, and the resilience of our operating model. While revenue declined year-over-year, adjusted EBITDA increased approximately 23%, with adjusted EBITDA margins expanding over 900 basis points, demonstrating the benefits of our improved product mix and cost management initiatives.”

Stephen L. Silvestro, OptimizeRx CEO

“While in-year contracted revenue continues to track below prior-year levels, resulting in a revision to our full-year 2026 revenue outlook, we remain encouraged by the growth we are seeing in contracted revenue for 2027, highlighting a start to a strong RFP season.”

Stephen L. Silvestro, OptimizeRx CEO

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.